Back to Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 4

A review of esomeprazole in the treatment of gastroesophageal reflux disease (GERD)

Authors Evangelos Kalaitzakis, Einar Björnsson

Published 15 September 2007 Volume 2007:3(4) Pages 653—663

Evangelos Kalaitzakis, Einar Björnsson

Department of Internal Medicine, Section of Gastroenterology and Hepatology, Sahlgrenska University Hospital, Gothenburg, Sweden

Abstract: Proton-pump inhibitors (PPIs) are the drugs of choice for the treatment of gastroesophageal reflux disease (GERD). Esomeprazole is the latest PPI and was developed as the S-isomer of omeprazole as an attempt to improve its pharmacokinetic properties. Esomeprazole has been reported to have a somewhat higher potency in acid inhibition than other PPIs. Despite some controversy, data from clinical trials and meta-analyses indicate that esomeprazole 40 mg od for up to 8 weeks provided higher rates of healing of erosive GERD and a greater proportion of patients with sustained resolution of heartburn, than omeprazole 20 mg, lansoprazole 30 mg, or pantoprazole 40 mg od. Esomeprazole 20 mg od has also been shown to be more effective in maintaining healing of erosive GERD compared with lansoprazole 15 mg od or pantoprazole 20 mg od. However, it is not clear whether these statistically significant differences are of major clinical importance. Esomeprazole 20 mg od is superior to placebo for treatment of non-erosive reflux disease (NERD) but clinical trials have not shown any significant differences in efficacy between esomeprazole 20 mg and omeprazole 20 mg or pantoprazole 20 mg od. Lastly, although esomeprazole treatment in GERD has been reported to result in improvement of health-related quality of life (QoL) indices, no clinical trials have evaluated the possible differential effects of different PPIs on QoL in GERD.

Keywords: esomeprazole, gastro-esophageal reflux disease (GERD), esophagitis, proton pump inhibitors

Download Article [PDF] 

Readers of this article also read:

Functional analysis of tanshinone IIA that blocks the redox function of human apurinic/apyrimidinic endonuclease 1/redox factor-1

Sui J, Li M, Qian C, Wang S, Cheng Y, Chen BP, Wang D

Drug Design, Development and Therapy 2014, 8:2147-2160

Published Date: 3 November 2014

Passing through the renal clearance barrier: toward ultrasmall sizes with stable ligands for potential clinical applications

Zhang XD, Yang J, Song SS, Long W, Chen J, Shen X, Wang H, Sun YM, Liu PX, Fan S

International Journal of Nanomedicine 2014, 9:2069-2072

Published Date: 25 April 2014

Maximum opening of the mouth by mouth prop during dental procedures increases the risk of upper airway constriction

Hiroshi Ito, Hiroyoshi Kawaai, Shinya Yamazaki, et al

Therapeutics and Clinical Risk Management 2010, 6:239-248

Published Date: 12 May 2010

Developments in the management of autosomal dominant polycystic kidney disease

Amirali Masoumi, Berenice Reed-Gitomer, Catherine Kelleher, Mir Reza Bekheirnia, Robert W Schrier

Therapeutics and Clinical Risk Management 2008, 4:393-407

Published Date: 11 April 2008

Analysis of adherence to national nosocomial pneumonia treatment guidelines

Edward H Eiland III, Kurt A Wargo, Wayne Hamm, Ali AM Hassoun

Therapeutics and Clinical Risk Management 2007, 3:983-988

Published Date: 15 January 2008

Obstructive sleep apnea and cardiovascular risk

Punginathn Dorasamy

Therapeutics and Clinical Risk Management 2007, 3:1105-1111

Published Date: 15 January 2008

The renaissance of fixed dose combinations: Combivir

Simon D Portsmouth, Christopher J Scott

Therapeutics and Clinical Risk Management 2007, 3:579-583

Published Date: 15 September 2007

How should we measure medication adherence in clinical trials and practice?

Jeannie K Lee, Karen A Grace, Terri G Foster, Monica J Crawley, Goldina I Erowele, et al

Therapeutics and Clinical Risk Management 2007, 3:685-690

Published Date: 15 September 2007